Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5881
    -0.0025 (-0.42%)
     

  • NZD/EUR

    0.5529
    -0.0016 (-0.29%)
     

  • ALL ORDS

    7,801.50
    -97.40 (-1.23%)
     

  • ASX 200

    7,550.40
    -91.70 (-1.20%)
     

  • OIL

    84.70
    +1.97 (+2.38%)
     

  • GOLD

    2,398.70
    +0.70 (+0.03%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,183.66
    -202.21 (-1.23%)
     

  • NIKKEI 225

    37,096.08
    -983.62 (-2.58%)
     

  • NZD/JPY

    90.7710
    -0.4830 (-0.53%)
     

Tecan schedules conference call on August 17th to discuss half year 2022 financial results

Tecan Group AG
·2-min read
Tecan Group AG
Tecan Group AG

Männedorf, Switzerland, August 10, 2022 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2022 on Wednesday, August 17th, 2022 at 09:00 CEST. The results will be published on August 17th, 2022 at 6:30 CEST.

The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the "Investor Relations" section of Tecan's website www.tecan.com.

Interested parties can also listen to the conference call by phone.

The dial-in numbers for the call are as follows:
Participants from Europe: +41 (0) 58 310 50 00 or +44 (0) 207 107 0613 (UK)
Participants from the U.S.: +1 (1) 631 570 56 13

ADVERTISEMENT

Participants should if possible dial in 15 minutes before the start of the event.

On August 17th, the full 2022 Interim Report will be available on the company website www.tecan.com under Investor Relations.

About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2021, Tecan generated sales of CHF 947 million (USD 1,041 million; EUR 877 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment